Lidocaine:

Either in favor of opting for a regional technique that allows us to maintain an adequate analgesic blockade and allows, among other things, to reduce the dose of major intravenous opiates such as morphine, as well as for the benefits of local anesthetics per se; The use of lidocaine intraoperatively and postoperatively has great implications for tumor recurrence in cancer patients who undergo surgery. In the first place, it allows a marked reduction in plasma concentrations of cortisol and catecholamines secondary to the decrease in endocrine-metabolic responses triggered by tissue destruction related to surgery. Second, they act directly by increasing the activity of NK cells and CD8+ T lymphocytes; vital cells to maintain the integrity of cellular immunity.

NSAIDs:

The hyper-functioning of COX-2 secondary to its overproduction in some types of tumors; results in increased synthesis of PGE2, which inhibits NK cell activity, increases angiogenesis, and decreases cell apoptosis, favoring tumor progression. The use of COX-2 type NSAIDs reduces the synthesis of PGE2, favoring immunosurveillance with its positive effects on immunity.
